Immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD-1/PD-L, have demonstrated significant clinical effects on the neutralization of immunosuppressive mechanisms in the tumor microenvironment (TME). Over the years, tremendous advances have been made in cancer immunotherapy, yet we are far from discovering the cure for the disease.

This is the first textbook of its kind devoted to describing the biological complexities of breast cancer in a way that is relevant to the radiation oncologist. Radiation Oncology has long treated breast cancer as a single biological entity, with all treatment decisions being based on clinical and pathologic risk factors. We are now beginning to understand that biological subtypes of breast cancer may have different risks of recurrence as well as different intrinsic sensitivity to radiotherapy. Multi-gene arrays that have for years been used to predict the risk of distant recurrence and the value of systemic chemotherapy may also have utility in predicting the risk of local recurrence. Additionally, the targeted agents used to treat breast cancer may interact with radiotherapy in ways that can be beneficial or undesirable. All of these emerging issues are extensively discussed in this book, and practical evidence-based treatment recommendations are presented whenever possible.

Nanotechnology for Drug Delivery and Pharmaceutical Sciences presents various drug-delivery techniques that utilize nanotechnology for the biomedical domain, highlighting both therapeutic and diagnostic applications. The book provides important facts and detailed studies on different promising nanocarriers like liposomes, exosomes and virus-based nanocarriers. Moreover, it explores these nanocarriers' utilization in the therapeutic applications of various diseases such as cancer, inflammation, neurodegenerative disorders like Huntington's disease, Alzheimer's disease, human immunodeficiency virus (HIV), and inflammatory bowel disease. In addition, the book describes how nanotechnology has efficiently overtaken conventional dosage forms and provided comfort and ease to patients. Relevant information regarding market trends, patents and social-economic factors are also provided, making this the perfect reference for doctors, researchers and scientists working in the fields of medicine, biochemistry, biotechnology, nanobiotechnology and the pharmaceutical sciences. - Gives a brief description of the utilization of nanotechnology in the drug-delivery domain - Highlights the properties of nanocarriers, their diagnostic and imaging applications, and their potential role in clinical diagnosis - Focuses on future developments and possibilities, allowing readers to enhance and explore the remaining gaps

This book is a comprehensive resource for veterinary oncologists and trainees, covering therapeutic strategies used in the treatment of veterinary patients. In the setting of a rapidly changing field like oncology, this timely text focuses on mechanisms of action and biological rationale rather than current specific clinical recommendations, allowing current and future clinicians to adapt treatment approaches as our understanding of the biology of cancer evolves. With each chapter written by experts in their field, this book provides informative figures that convey this biological understanding and rationale of therapy. It starts from the mechanisms of treatment as we currently understand them, covering radiation therapy, chemotherapy, immunotherapy, targeted therapy, and many more. Dispensing vital, detailed and practical information about the different therapeutic strategies available, this book is a vital resource for practicing veterinarians, while also providing students of veterinary oncology with a better understanding of the key differences between different treatment strategies.

Cancer immunotherapy is based on using the immune system components to fight tumors, without destroying normal cells. Several immunotherapeutic strategies have been investigated and proposed for the treatment of cancers, including cancer vaccines containing tumor antigens that are used to induce immune responses against tumors, monoclonal antibodies against tumor antigens, and immune checkpoint inhibitors. However, many clinical trials have shown that the use of these methods as monotherapy is ineffective in many cases. Many tumors can resist immunotherapy due to the absence or insufficient infiltration of tumors with CD8+ T cells and hence, are called “cold” or non-inflammatory tumors. Cold tumors are characterized by a lack of infiltrating CD8+ T cells, the presence of anti-inflammatory myeloid cells, tumor-associated M2 macrophages, and regulatory T cells. A combination of other cancer therapeutic approaches, such as chemotherapy or immunotherapy with cancer vaccines, could dramatically enhance the efficacy and, eventually, the outcome of the treatment. Despite some success of the immunotherapy of oncological diseases, cold tumors represent one of the main therapeutic challenges for modern immunotherapy. It can be expected that in the near future, treatment algorithms will be developed to adapt the therapeutic strategies to the immune context of the tumor since treatment with checkpoint inhibitors or vaccines alone is not enough for cold tumors. Therefore, using other therapeutic approaches alongside the existing treatment methods can be more reasonable for cold tumors that do not strongly stimulate the immune system or resist against it. To apply targeted treatments such as the use of small molecules, small peptides, hybrid small molecules, biologically active peptides, non-protein isolates of food products or by-products, and every material that is capable of the disturbing immunosuppressive tumor microenvironment (TME) as an adjuvant therapy can reduce the resistance of cold tumors to immunotherapy which is so-called turning them into “warm” tumors. This research topic aims to cover all outstanding advances in immunology, medical chemistry and biochemistry, pharmacology, food engineering and molecular biology of contemporary molecular drug targets involved in cancer treatment and encompasses the following subjects: • Definition and explanation of cold tumors and challenges ahead toward their treatment • Designing and application of small peptides, small molecules, and other similar materials to overcome suppressive TME and break tumors resistance • Extraction and preparation of bioactive peptides or other components derived from natural resources to make cold tumor barriers fragile • Modifications and alterations leading to overcoming cold tumor resistance against cancer vaccines and ICP inhibitors Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.

Foreword from the Editor: With the second installment in the Quarterly Highlights series, Frontiers in Oncology has once again had a strong quarter, and continues to publish important research, with submissions from across the globe - and readership from across the globe. In this quarter, we saw a number of different impact metrics become updated using recent data. The 2019 impact metrics reflect our competitive and respectable status in the field and amongst competitors. We find it very encouraging to see that our impact has remained high, and thank the entirety of the Editorial Board and Office for their contributions and hard work in doing so. Once again with a record-breaking number of papers to choose from, this Special Edition takes an interdisciplinary approach to highlight important recent findings across the different areas of cancer research. We have opted for a selection of papers that we feel best demonstrates the interdisciplinary and international nature of the journal. We are pleased to announce that we have begun our work on launching a new section in the journal. The new section, which will be our 19th, will focus on dermatological malignancies and cancers of the skin. Given the importance and relevance of skin cancers in today’s climate, we are very excited to be moving forward with this. The journal has been active and present at a number of conferences including the 1st International Lung Cancer Summit, the 15th International Conference on Malignant Lymphoma, and ESMO’s World Congress on Gastrointestinal Cancers. The Editorial Office will also be present at the ESMO 2019 Congress in Barcelona next month (Booth P425) and look forward to meeting our readers and Editors there. Giuseppe Giaccone